文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

托珠单抗治疗秋水仙碱抵抗或不耐受家族性地中海热:多中心随机双盲安慰剂对照试验方案

Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2018-12-29

本研究为研究者发起的III期多中心随机双盲平行组试验,在日本9个中心比较托珠单抗与安慰剂在秋水仙碱抵抗或不耐受家族性地中海热患者中的疗效与安全性。计划纳入24例受试者,随机接受每周皮下注射托珠单抗162 mg或安慰剂,持续24周。主要终点为至24周发热发作次数。

要点

  • 托珠单抗每周皮下162 mg对比安慰剂,用于秋水仙碱抵抗或不耐受FMF患者。
  • 主要终点为24周内发热发作次数,次要终点包括发作伴随症状、CRP、SAA等。
  • 该随机双盲试验旨在评估托珠单抗在此类FMF患者中的疗效与安全性。

核心结论

  • 该试验旨在评估托珠单抗改善秋水仙碱抵抗或不耐受FMF患者临床病程与结局的疗效。

研究设计与样本

  • III期研究者发起、多中心、双盲、随机、平行组试验,在日本9个中心开展。
  • 计划纳入24例秋水仙碱抵抗或不耐受FMF患者,随机分为托珠单抗组12例和安慰剂组12例。
  • 干预为每周皮下注射托珠单抗162 mg或安慰剂,持续24周,符合救援标准时允许救援治疗。

主要发现

  • 原文未报告研究结果,尚待试验完成后产出证据。

关键数值与推荐

  • 主要终点为至24周发热发作次数。
  • 次要终点包括发作伴随症状发生次数、至发热发作时间、发热发作持续时间、血清CRP和SAA、36项短表健康调查、医师总体评价(100 mm视觉模拟量表)、体温、12周和24周达到FMF 50的受试者百分比。
  • 药效学评估包括血清托珠单抗水平和可溶性IL-6受体测定。

临床怎么用

  • 该试验结果将为托珠单抗用于秋水仙碱抵抗或不耐受FMF提供随机对照证据,暂不改变现行临床实践。

局限性

  • 原文未报告研究结果,无法评估疗效与安全性。
  • 计划样本量仅24例,统计效能可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Familial Mediterranean fever (FMF) is an inherited disorder caused by a number of mutations of the Mediterranean fever (MEFV) gene, coding a protein named pyrin that acts as a major regulatory component of the inflammasome. The first-line drug for FMF treatment is colchicine, but 10% of patients with FMF do not respond well to colchicine. Although the efficacy of tocilizumab (TCZ), which is a recombinant, humanized, antihuman interleukin 6 (IL-6) receptor monoclonal antibody, has been reported to prevent FMF attacks, the effects of TCZ on individuals with colchicine-resistant or colchicine-intolerant FMF have not been evaluated in a randomized clinical trial. METHODS/DESIGN: In this phase III, investigator-initiated, multicenter, double-blind, randomized, parallel-group trial, the efficacy and safety of TCZ will be compared with placebo in patients with colchicine-resistant or colchicine-intolerant FMF. The study will be conducted in nine centers in Japan. Participants (n = 24) will be randomly assigned to receive 162 mg of TCZ (n = 12) or placebo (n = 12) administered subcutaneously once weekly for 24 weeks. Rescue treatment will be allowed if rescue criteria are met. A primary endpoint is the number of fever attacks until 24 weeks. Secondary endpoints include the number of occurrences of accompanying symptoms during attacks; the time until a fever attack occurs; the duration of fever attacks; serum C-reactive protein and serum amyloid A; 36-item Short Form Health Survey; general evaluation by a physician (100-mm visual analogue scale); body temperature; the percentage of subjects who achieve FMF 50 at 12 weeks and 24 weeks; and pharmacodynamic assessment, including the measurement of serum TCZ level and soluble IL-6 receptor. DISCUSSION: The study is expected to produce evidence regarding the efficacy of a potential new therapeutic agent, TCZ, in improving the clinical course and outcome for patients with colchicine-resistant or colchicine-intolerant FMF. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry, UMIN000028010 . Registered on 7 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Koga T, Sato S, Miyamoto J, et al. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2018. PMID: 30594222. doi:10.1186/s13063-018-3105-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。